In silico design of fusion protein of FimH from uropathogenic Escherichia coli and MrpH from Proteus mirabilis against urinary tract infections


1 Department of Molecular Biology, Pasteur Institute of , Tehran, Iran

2 Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran


Background: Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) and Proteus mirabilis are the most important pathogens causing UTIs. The FimH from type 1 pili of UPEC and the MrpH from P. mirabilis play critical roles in the UTI process and have presented as ideal vaccine candidates against UTIs. There is no effective vaccine against UTI and the development of an ideal UTI vaccine is required.
Materials and Methods: In this study, we planned to design a novel fusion protein of FimH from UPEC and MrpH from P. mirabilis. For this purpose, we modeled fusion protein forms computationally using the Iterative Threading Assembly Refinement (I-TASSER) server and evaluated their interactions with toll-like receptor 4 (TLR4). The best fusion protein was constructed using overlap extension polymerase chain reaction (OE-PCR) and the biological activity of fusion was evaluated by the induction of interleukin-8 (IL-8) in the HT-29 cell line.
Results: Our study indicated that based on the Protein Structure Analysis (ProSA)-web and the docking results, MrpH.FimH showed better results than did FimH.MrpH, and it was selected for construction. The results of bioassay on the HT-29 showed that FimH and MrpH.FimH induced significantly higher IL-8 responses than untreated cells or MrpH alone in the cell line tested.
Conclusions: In the present study, we designed and constructed the novel fusion protein MrpH.FimH from UPEC and P. mirabilis based on in silico methods. Our bioassay results indicate that the MrpH.FimH fusion protein is active and capable of inducing immune responses.


Dhakal BK, Kulesus RR, Mulvey MA. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest 2008;38(Suppl 2):2-11.  Back to cited text no. 1
Ragnarsdóttir B, Fischer H, Godaly G, Grönberg-Hernandez J, Gustafsson M, Karpman D, et al. TLR- and CXCR1-dependent innate immunity: Insights into the genetics of urinary tract infections. Eur J Clin Invest 2008;38(Suppl 2):12-20.  Back to cited text no. 2
Cusumano CK, Hung CS, Chen SL, Hultgren SJ. Virulence plasmid harbored by uropathogenic Escherichia coli functions in acute stages of pathogenesis. Infect Immun 2010;78:1457-67.  Back to cited text no. 3
Schwartz DJ, Kalas V, Pinkner JS, Chen SL, Spaulding CN, Dodson KW, et al. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc Natl Acad Sci USA 2013;110:15530-7.  Back to cited text no. 4
Li X, Mobley HL. Vaccines for Proteus mirabilis in urinary tract infection. Int J Antimicrob Agents 2002;19:461-5.  Back to cited text no. 5
Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 2008;21:26-59.  Back to cited text no. 6
Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 2012;36:616-48.  Back to cited text no. 7
Billips BK, Yaggie RE, Cashy JP, Schaeffer AJ, Klumpp DJ. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis 2009;200:263-72.  Back to cited text no. 8
Alamuri P, Eaton KA, Himpsl SD, Smith SN, Mobley HL. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Infect Immun 2009;77:632-41.  Back to cited text no. 9
Langermann S, Ballou WR Jr. Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 2001;183(Suppl 1):S84-6.  Back to cited text no. 10
Wright KJ, Seed PC, Hultgren SJ. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 2007;9:2230-41.  Back to cited text no. 11
Li X, Lockatell CV, Johnson DE, Lane MC, Warren JW, Mobley HL. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infect Immun 2004;72:66-75.  Back to cited text no. 12
Hagan EC, Mobley HL. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infect Immun 2007;75:3941-9.  Back to cited text no. 13
Billips BK, Schaeffer AJ, Klumpp DJ. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder. Infect Immun 2008;76:3891-900.  Back to cited text no. 14
Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007;25:763-75.  Back to cited text no. 15
Honko AN, Sriranganathan N, Lees CJ, Mizel SB. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006;74:1113-20.  Back to cited text no. 16
Mossman KL, Mian MF, Lauzon NM, Gyles CL, Lichty B, Mackenzie R, et al. Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand. J Immunol 2008;181:6702-6.  Back to cited text no. 17
Bahrani FK, Massad G, Lockatell CV, Johnson DE, Russell RG, Warren JW, et al. Construction of an MR/P fimbrial mutant of Proteus mirabilis: Role in virulence in a mouse model of ascending urinary tract infection. Infect Immun 1994;62:3363-71.  Back to cited text no. 18
Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 1999;112:531-52.  Back to cited text no. 19
Sen TZ, Jernigan RL, Garnier J, Kloczkowski A. GOR V server for protein secondary structure prediction. Bioinformatics 2005;21:2787-8.  Back to cited text no. 20
Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 1999;292:195-202.  Back to cited text no. 21
Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008;9:40.  Back to cited text no. 22
Wiederstein M, Sippl MJ. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 2007;35:W407-10.  Back to cited text no. 23
Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: Phi, psi and Cbeta deviation. Proteins 2003;50:437-50.  Back to cited text no. 24
Ritchie DW, Venkatraman V. Ultra-fast FFT protein docking on graphics processors. Bioinformatics 2010;26:2398-405.  Back to cited text no. 25
Asadi KM, Oloomi M, Habibi M, Bouzari S. Cloning of fimH and fliC and expression of the fusion protein FimH/FliC from Uropathogenic Escherichia coli (UPEC) isolated in Iran. Iran J Microbiol 2012;4:55-62.  Back to cited text no. 26
Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, et al. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 2007;9:821-8.  Back to cited text no. 27
Ulett GC, Totsika M, Schaale K, Carey AJ, Sweet MJ, Schembri MA. Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection. Curr Opin Microbiol 2013;16:100-7.  Back to cited text no. 28
Wieser A, Romann E, Magistro G, Hoffmann C, Nörenberg D, Weinert K, et al. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 2010;78:3432-42.  Back to cited text no. 29
Savar NS, Jahanian-Najafabadi A, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. J Biotechnol 2014;175:31-7.  Back to cited text no. 30
Soria-Guerra RE, Moreno-Fierros L, Rosales-Mendoza S. Two decades of plant-based candidate vaccines: A review of the chimeric protein approaches. Plant Cell Rep 2011;30:1367-82.  Back to cited text no. 31
Mian MF, Lauzon NM, Andrews DW, Lichty BD, Ashkar AA. FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther 2010;18:1379-88.  Back to cited text no. 32
Ashkar AA, Mossman KL, Coombes BK, Gyles CL, Mackenzie R. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog 2008;4:e1000233.  Back to cited text no. 33